Long-term Outcomes in Lean and Non-lean NAFLD Patients: a Systematic Review and Meta-analysis

Overview

Journal Endocrine

Specialty Endocrinology

Date 2023 May 30

PMID 37253855

Authors

Shaomin Huang

Yun Bao

Nawen Zhang

RuiLan Niu

Limin Tian

Affiliations

Soon will be listed here.

Abstract

Background: Although nonalcoholic fatty liver disease (NAFLD) commonly occurs in overweight or obese individuals, it is increasingly being identified in the lean population. The association between lean and an increased risk of all-cause mortality among patients with NAFLD remains controversial. We aimed to perform a systematic review and meta-analysis of the literature to evaluate this association and compare the long-term outcomes of lean NAFLD patients and non-lean NAFLD patients.

Methods: For this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wan Fang, and Chinese Biomedical Literature Database (CBM) from inception to October 15, 2021, for relevant original research articles without any language restrictions. Our primary outcome was to compare the all-cause mortality in lean NAFLD patients and non-lean NAFLD patients by qualitative synthesis. Relative risks (RRs) and corresponding 95% confidential intervals (CIs) were pooled with a random effect model. Heterogeneity was evaluated using I-squared (I²) statistics while publication bias was determined using Egger's tests. Subgroup and sensitivity analyses were performed. As for secondary outcomes, we estimated total, cardiovascular, and liver-related mortality, as well as the incidence of diabetes, hypertension, cirrhosis, and cancer in lean and non-lean individuals with NAFLD by quantitative synthesis. Person-years of follow-up were used as the denominator to estimate the mortality and incidence.

Results: We identified 12 studies (n = 26,329), 7 of which (n = 7924) were used to evaluate the risk of all-cause mortality between lean and non-lean NAFLD patients. Lean patients with NAFLD were found to be at an elevated risk of death compared to non-lean patients (RR = 1.39, 95% CI 1.08-1.82, heterogeneity: I² = 43%). Among the lean NAFLD population, all-cause mortality was 13.3 (95% CI: 6.7-26.1) per 1000 person-years, 3.6 (95% CI: 1.0-11.7) for liver-related mortality, and 7.7 (95% CI: 6.4-9.2) for cardiovascular-related mortality. The incidence of new-onset diabetes was 13.7 (95% CI 8·2-22.7) per 1000 person-years, new-onset hypertension was 56.1 (95% CI: 40.2-77.9), cirrhosis was 2.3 (95% CI: 1.0-5.0), and cancer was 25.7 (95% CI: 20.3-32.4).

Conclusions: Lean patients with NAFLD had a higher risk of all-cause death than non-lean patients. Body mass index (BMI) should not be used as a criterion to determine whether further observation and therapy of patients with NAFLD are warranted.

Citing Articles

Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China.

Zhu R, Xu C, Jiang S, Xia J, Wu B, Zhang S Eur J Med Res. 2025; 30(1):137.

PMID: 40001266 PMC: 11863909. DOI: 10.1186/s40001-025-02373-1.

A simple, reliable and easily generalizable cell-based assay for screening potential drugs that inhibit lipid accumulation.

Yang W, Pan Q, Li Q, Zhou S, Cao X Curr Res Toxicol. 2025; 8():100213.

PMID: 39834517 PMC: 11743863. DOI: 10.1016/j.crtox.2024.100213.

Analysis of the association between non-alcoholic fatty liver disease and mortality in United States adults.

Rong F, Mai Y, Shou L, Zhu X, Li M, Zhu L Front Nutr. 2024; 11:1502671.

PMID: 39650715 PMC: 11620881. DOI: 10.3389/fnut.2024.1502671.

Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review.

Njei B, Ameyaw P, Al-Ajlouni Y, Njei L, Boateng S Cureus. 2024; 16(10):e71451.

PMID: 39544615 PMC: 11560387. DOI: 10.7759/cureus.71451.

Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease: findings from NHANES 1999-2018.

Liu W, Yang X, Zhan T, Huang M, Tian X, Tian X Front Endocrinol (Lausanne). 2024; 15:1457869.

PMID: 39403588 PMC: 11471496. DOI: 10.3389/fendo.2024.1457869.

References

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Huang J, Yu M, Chuang W . Simulation of Long-term Outcomes in Patients With Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2022; 5(9):e2230436. DOI: 10.1001/jamanetworkopen.2022.30436. View

Younossi Z, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y . The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016; 64(5):1577-1586. DOI: 10.1002/hep.28785. View

Sookoian S, Pirola C . Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017; 46(2):85-95. DOI: 10.1111/apt.14112. View

Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa M . Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord. 2021; 22(2):351-366. PMC: 8893229. DOI: 10.1007/s11154-020-09621-1. View

Ye Q, Zou B, Yeo Y, Li J, Huang D, Wu Y . Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(8):739-752. DOI: 10.1016/S2468-1253(20)30077-7. View

Machado M, Marques-Vidal P, Cortez-Pinto H . Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45(4):600-6. DOI: 10.1016/j.jhep.2006.06.013. View

Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G . Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004; 5(1):27-42. DOI: 10.1111/j.1467-789x.2004.00126.x. View

10.

Ahmed O, Gidener T, Mara K, Larson J, Therneau T, Allen A . Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clin Gastroenterol Hepatol. 2021; 20(6):1374-1381.e6. PMC: 8755855. DOI: 10.1016/j.cgh.2021.07.016. View

11.

Feldman A, Wernly B, Strebinger G, Eder S, Zandanell S, Niederseer D . Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects. J Gastrointestin Liver Dis. 2021; 30(3):366-373. DOI: 10.15403/jgld-3622. View

12.

Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R . Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2018; 2(1):48-57. PMC: 5776871. DOI: 10.1002/hep4.1124. View

13.

Leung J, Loong T, Wei J, Wong G, Chan A, Choi P . Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2016; 65(1):54-64. DOI: 10.1002/hep.28697. View

14.

Xun Y, Guo J, Lou G, Jiang Y, Zhuang Z, Zhu M . Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. Clin Exp Pharmacol Physiol. 2014; 41(9):643-9. DOI: 10.1111/1440-1681.12260. View

15.

Sinn D, Kang D, Cho S, Paik S, Guallar E, Cho J . Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. Eur J Endocrinol. 2019; 181(2):185-192. DOI: 10.1530/EJE-19-0143. View

16.

Niriella M, Kasturiratne A, Pathmeswaran A, De Silva S, Perera K, Subasinghe S . Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepatol Int. 2018; 13(3):314-322. DOI: 10.1007/s12072-018-9916-4. View

17.

Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T . The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int. 2015; 36(2):275-83. DOI: 10.1111/liv.12912. View

18.

Golabi P, Paik J, Arshad T, Younossi Y, Mishra A, Younossi Z . Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun. 2020; 4(8):1136-1148. PMC: 7395070. DOI: 10.1002/hep4.1534. View

19.

Wang L . Ultrasound-Diagnosed Nonalcoholic Fatty Liver Disease Independently Predicts a Higher Risk of Developing Diabetes Mellitus in Nonoverweight Individuals. Acad Radiol. 2018; 26(7):863-868. DOI: 10.1016/j.acra.2018.08.019. View

20.

Golabi P, Paik J, Fukui N, Locklear C, de Avilla L, Younossi Z . Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019; 37(1):65-72. PMC: 6336127. DOI: 10.2337/cd18-0026. View